News

GloPID-R Zika Virus Research Workshop was held in Sao Paulo, Brazil on November 30 – December 2, 2016. The workshop’s aim was to identify and establish collaboration and synergies between the research and capacity development projects in support of the Zika virus response in Latin America and the Caribbean funded by GloPID-R members worldwide. EVI was represented by Nicola Viebig.

Two new influenza reagents are now available. Influenza anti-A/Michigan/45/2015-like HA serum and Influenza Antigen A/Singapore/GP1908/2015 serum are now available through the NIBSC website.

The deadline for oral abstract submissions is Friday 2nd December 2016.

SAP has released a short video featuring the European Vaccine Initiative. See how the use of the SAP system is helping EVI to simplify the management process. The video is available on the EVI YouTube channel.

The Influenza anti-A Switzerland/9715293/2013-Like HA serum (sheep 618, 619, 628, 634, 635 & 636) is now available on the NIBSC website.

EVI extends a warm welcome to Siaka Débé. Mr Débé joins EVI with a fellowship from the European and Developing Countries’ Clinical Trials Partnership (EDCTP)/ Tropical Diseases Research-World Health Organization (TDR/WHO). He began his one-year Clinical Research and Development fellowship on 14 November.  

The ASTMH Council in partnership with the Bill & Melinda Gates Foundation, announce a call for applications for the recently launched Alan J. Magill Fellowship, set up to honour the life and work of Alan J. Magill.

New members of the DCVMN Executive Committee were elected by corporate members during the 17th DCVMN Annual General Meeting. EVI congratulates the newly elected President Ms. Mahima Datla, CEO of Biological E Limited in India.

The European Union launched calls to support research on emerging diseases with a substantial investment from the Horizon2020 programme.

Time to register for ADVAC 2017!

Until 15 November 2016.